Evaluating the Efficacy of Secondary Transurethral Resection of the Bladder for High-grade Ta Tumors

Overview

Journal Investig Clin Urol

Specialty Urology

Date 2022 Jan 4

PMID 34983118

Authors

Kyeongchae Lee

Seung-Hwan Jeong

Sang-Hyun Yoo

Ja Hyeon Ku

Affiliations

Soon will be listed here.

Abstract

Purpose: The need for secondary transurethral resection of the bladder (re-TURB) in patients with high-grade Ta tumors has not been assessed. This study aimed to compare the outcomes of patients with high-grade Ta tumors who did and did not undergo re-TURB.

Materials And Methods: This study used data from the Seoul National University Prospectively Enrolled Registry for Urothelial Cancer-Transurethral Bladder Tumor Resection (SUPER-UC-TURB). Patients with high-grade Ta tumors who underwent TURB between March 2016 and December 2019 were included. Following the initial TURB, if the pathology results showed a tumor grade higher than high-grade Ta, re-TURB was performed according to the surgeon's recommendation. The recurrence-free survival rate was assessed by Kaplan-Meier analysis and Cox regression analysis between patients who did and did not undergo re-TURB.

Results: In total, 187 patients with high-grade Ta who underwent initial TURB were included, of whom 115 underwent re-TURB and 72 did not. Patients in the re-TURB group had a significantly higher 2-year recurrence-free survival rate than did those in the no re-TURB group (81.3% vs. 60.1%; p=0.005). Whether patients underwent re-TURB was a significant predictor of the risk of bladder cancer recurrence in both the univariate (HR, 0.52; 95% CI, 0.27-0.98; p=0.044) and multivariate (HR, 0.41; 95% CI, 0.19-0.97; p=0.041) analysis.

Conclusions: The risk for bladder cancer recurrence was increased, and the 2-year recurrence-free survival was significantly decreased, in patients with high-grade Ta tumors who did not undergo re-TURB. Thus, re-TURB is beneficial in patients with high-grade Ta bladder cancer.

Citing Articles

Repeat TURBT in large volume high-grade non-invasive bladder cancer.

Durant A, Nguyen M, Choudry M, Mi L, Andrews J, Tyson M Bladder Cancer. 2025; 10(4):270-277.

PMID: 40035080 PMC: 11864239. DOI: 10.1177/23523735241303350.

Intravesical chemotherapy in BCG waiting period may prolong time to recurrence for high-risk NMIBC patients.

Li Z, Wang Z, Wu J, Zhang F, Gan L, Wang W BMC Cancer. 2025; 25(1):268.

PMID: 39953419 PMC: 11829350. DOI: 10.1186/s12885-025-13705-z.

IVC treatment between primary and second TURBT may improve the prognosis of high-risk NMIBC patients receiving BCG treatment.

Li Z, Wang Z, Liu Y, Yang L, Gu L, Li H Sci Rep. 2025; 15(1):4874.

PMID: 39930090 PMC: 11811208. DOI: 10.1038/s41598-025-89008-x.

References

Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comperat E . EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol. 2016; 71(3):447-461. DOI: 10.1016/j.eururo.2016.05.041. View

Quhal F, DAndrea D, Soria F, Moschini M, Abufaraj M, Roupret M . Primary Ta high grade bladder tumors: Determination of the risk of progression. Urol Oncol. 2020; 39(2):132.e7-132.e11. DOI: 10.1016/j.urolonc.2020.07.017. View

Herr H . Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome. J Urol. 1999; 163(1):60-1; discussion 61-2. View

Stein J, Lieskovsky G, Cote R, Groshen S, Feng A, Boyd S . Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001; 19(3):666-75. DOI: 10.1200/JCO.2001.19.3.666. View

Cheng L, NEUMANN R, Weaver A, Spotts B, Bostwick D . Predicting cancer progression in patients with stage T1 bladder carcinoma. J Clin Oncol. 1999; 17(10):3182-7. DOI: 10.1200/JCO.1999.17.10.3182. View

Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F . Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur Urol. 2016; 71(1):96-108. DOI: 10.1016/j.eururo.2016.06.010. View

Sylvester R, van der Meijden A, Oosterlinck W, Witjes J, Bouffioux C, Denis L . Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006; 49(3):466-5. DOI: 10.1016/j.eururo.2005.12.031. View

David K, Mallin K, Milowsky M, Ritchey J, Carroll P, Nanus D . Surveillance of urothelial carcinoma: stage and grade migration, 1993-2005 and survival trends, 1993-2000. Cancer. 2009; 115(7):1435-47. DOI: 10.1002/cncr.24147. View

Herr H . The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol. 1999; 162(1):74-6. DOI: 10.1097/00005392-199907000-00018. View

10.

Lazica D, Roth S, Brandt A, Bottcher S, Mathers M, Ubrig B . Second transurethral resection after Ta high-grade bladder tumor: a 4.5-year period at a single university center. Urol Int. 2013; 92(2):131-5. DOI: 10.1159/000353089. View

11.

Gupta A, Lotan Y, Bastian P, Palapattu G, Karakiewicz P, Raj G . Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy. Urology. 2008; 71(2):302-7. DOI: 10.1016/j.urology.2007.10.041. View

12.

Ayati M, Amini E, Damavand R, Nowroozi M, Soleimani M, Ranjbar E . Second Transurethral Resection of Bladder Tumor: Is it Necessary in All T1 and/or High-Grade Tumors?. Urol J. 2018; 16(2):152-156. DOI: 10.22037/uj.v0i0.4670. View

13.

Jeong C, Suh J, Yuk H, Tae B, Kim M, Keam B . Establishment of the Seoul National University Prospectively Enrolled Registry for Genitourinary Cancer (SUPER-GUC): A prospective, multidisciplinary, bio-bank linked cohort and research platform. Investig Clin Urol. 2019; 60(4):235-243. PMC: 6607078. DOI: 10.4111/icu.2019.60.4.235. View

14.

Divrik R, Sahin A . Re: Maurizio A. Brausi. Challenging the EAU guidelines regarding early repeat transurethral resection. Eur Urol Suppl 2011;10:e5-7. Eur Urol. 2012; 62(1):e21-2. DOI: 10.1016/j.eururo.2012.03.015. View

15.

Samaratunga H, Makarov D, Epstein J . Comparison of WHO/ISUP and WHO classification of noninvasive papillary urothelial neoplasms for risk of progression. Urology. 2002; 60(2):315-9. DOI: 10.1016/s0090-4295(02)01705-3. View

16.

Pan C, Chang Y, Chen K, Yu H, Sun C, Ho D . Prognostic significance of the 2004 WHO/ISUP classification for prediction of recurrence, progression, and cancer-specific mortality of non-muscle-invasive urothelial tumors of the urinary bladder: a clinicopathologic study of 1,515 cases. Am J Clin Pathol. 2010; 133(5):788-95. DOI: 10.1309/AJCP12MRVVHTCKEJ. View

17.

Burger M, Catto J, Dalbagni G, Grossman H, Herr H, Karakiewicz P . Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2012; 63(2):234-41. DOI: 10.1016/j.eururo.2012.07.033. View

18.

Song W, Jeon H . Incidence of kidney, bladder, and prostate cancers in Korea: An update. Korean J Urol. 2015; 56(6):422-8. PMC: 4462631. DOI: 10.4111/kju.2015.56.6.422. View